1. Thompson P.A. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves longterm diseasefree survival in IGHVmutated chronic lymphocytic leukemia // Blood. 2016. Vol. 127, N 3. P. 303–309.
2. Bottcher S. et al. Standardized MRD flow and ASO IGH RQPCR for MRD quantification in CLL patients after rituximabcontaining immunochemotherapy: a comparative analysis // Leukemia. 2009. Vol. 23, N 11. P. 2007–2017.
3. Bottcher S. et al. Comparative analysis of minimal residual disease detection using fourcolor flow cytometry, consensus IgHPCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation // Leukemia. 2004. Vol. 18, N 10. P. 1637–1645.
4. Fischer K. et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions // N. Engl. J. Med. 2019. Vol. 380, N 23. P. 2225–2236.
5. Goede V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions // N. Engl. J. Med. 2014. Vol. 370, N 12. P. 1101–1110.
6. Hallek M. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial // Lancet. 2010. Vol. 376, N 9747. P. 1164–1174.
7. Moreno C. et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in firstline treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, openlabel, phase 3 trial // Lancet Oncol. 2019. Vol. 20, N 1. P. 43–56.
8. Woyach J.A. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL // N. Engl. J. Med. 2018. Vol. 379, N 26. P. 2517–2528.
9. Sharman J.P. et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatmentnaive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial // Lancet. 2020. Vol. 395, N 10 232. P. 1278–1291.
10. Kassirskiĭ I.A., Volkova M.A. [Main problems of chronic lympheleukemia] // Ter. Arkh. 1970. Vol. 42, N 1. P. 8–15.
11. O’Brien S. et al. Singleagent ibrutinib in treatmentnaive and relapsed/refractory chronic lymphocytic leukemia: a 5year experience // Blood. 2018. Vol. 131, N 17. P. 1910–1919.
12. Burger J.A. et al. Longterm efficacy and safety of firstline ibrutinib treatment for patients with CLL/SLL: 5 years of followup from the phase 3 RESONATE2 study // Leukemia. 2020. Vol. 34, N 3. P. 787–798.
13. Mahon F.X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial // Lancet Oncol. 2010. Vol. 11, N 11. P. 1029–1035.
14. Ahn I.E. et al. Depth and durability of response to ibrutinib in CLL: 5year followup of a phase 2 study // Blood. 2018. Vol. 131, N 21. P. 2357–2366.
15. Hillmen P. et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study // J. Clin. Oncol. 2019. Vol. 37, N 30. P. 2722–2729.
16. Jain N. et al. Combined ibrutinib and venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) // Blood. 2019. Vol. 134, suppl. 1. P. 359–359.
17. Siddiqi T., Tam C.S., Allan J.N., Kipps T.J., Opat S., Tedeschi A. et al. Firstline ibrutinib (ibr) + venetoclax (Ven) for patients (Pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): efficacy and safety results from captivate MRD cohort // EHA Library. 2020. Vol. 12. P. S158.
18. Jain N. et al. Ibrutinib and venetoclax for firstline treatment of CLL // N. Engl. J. Med. 2019. Vol. 380, N 22. P. 2095–2103.
19. Noy A. et al. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol // Blood. 2001. Vol. 97, N 7. P. 1929–1936.
20. Vuillier F. et al. Evaluation of residual disease in Bcell chronic lymphocytic leukemia patients in clinical and bonemarrow remission using CD5CD19 markers and PCR study of gene rearrangements // Leuk. Lymphoma. 1992. Vol. 7, N 3. P. 195–204.
21. Provan D. et al. Eradication of polymerase chain reactiondetectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation // Blood. 1996. Vol. 88, N 6. P. 2228–2235.
22. van der Velden V.H. et al. Detection of minimal residual disease in hematologic malignancies by realtime quantitative PCR: principles, approaches, and laboratory aspects // Leukemia. 2003. Vol. 17, N 6. P. 1013–1034.
23. FDA authorizes first next generation sequencingbased test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma. 2018. URL: https://www.fda.gov/newsevents/pressannouncements/fdaauthorizesfirstnextgenerationsequenc ingbasedtestdetectverylowlevelsremainingcancer
24. Bruggemann M. et al. Standardized nextgeneration sequencing of immunoglobulin and Tcell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonalityNGS validation study // Leukemia. 2019. Vol. 33, N 9. P. 2241–2253.
25. Clavio M. et al. First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease // Eur. J. Haematol. 1998. Vol. 61, N 3. P. 197–203.
26. Fischer M., Klein U., Kuppers R. Molecular singlecell analysis reveals that CD5positive peripher al blood B cells in healthy humans are characterized by rearranged Vkappa genes lacking somatic mutation // J. Clin. Invest. 1997. Vol. 100, N 7. P. 1667–1676.